Genzyme, AGTC Announce Gene Therapy Collaboration

Genzyme Corporation and Applied Genetic Technologies (AGTC), a private development-stage biotechnology company, announced today that they have entered into a research collaboration to jointly develop novel therapeutics involving gene therapy.Through the collaboration, Genzyme gains access to AGTC’s extensive expertise using Adeno-Associated Virus (AAV) vectors to deliver genes to patients, including access to AGTC’s novel high-yield Read more about Genzyme, AGTC Announce Gene Therapy Collaboration[…]

Genzyme To Acquire SangStat Medical Corporation

Genzyme Corporation and SangStat Medical Corporation have reached an agreement under which Genzyme will acquire SangStat in an all cash transaction valued at $22.50 per outstanding share, or approximately $600 million. Genzyme expects to complete the acquisition in early September. The transaction is expected to be dilutive to Genzyme’s GAAP earnings due to amortization through Read more about Genzyme To Acquire SangStat Medical Corporation[…]